SCHEMBL15423494

SCHEMBL15423494

CC(C)CCCCC(O)C(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.48
TRPA1 O75762 1/20 0.48
LMNA P02545 2/20 0.48
SPHK1 Q9NYA1 2/20 0.41
BLM P54132 2/20 0.34
CYP2D6 P10635 2/20 0.33
CYP3A4 P08684 2/20 0.33
GMNN O75496 1/20 0.33
POLB P06746 1/20 0.33
THPO P40225 1/20 0.33
MTOR P42345 1/20 0.33
KDM4E B2RXH2 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
MAPT P10636 1/20 0.33
CETP P11597 1/20 0.33
HTT P42858 1/20 0.33
UBE2N P61088 1/20 0.33
KDM4C Q9H3R0 2/20 0.31
KDM4A O75164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3761524 0.94 LMNA (0.48) TRPV1TRPA1LMNASPHK1BLM
SCHEMBL31501273 0.88 TRPV1 (0.60) TRPV1TRPA1LMNASPHK1BLM
SCHEMBL5127737 0.84 TRPV1 (0.48) TRPV1TRPA1LMNASPHK1BLM
SCHEMBL16139792 0.81 TSHR (0.33) TRPV1TRPA1LMNACA1
SCHEMBL16139789 0.81 TSHR (0.33) TRPV1TRPA1LMNACA1
SCHEMBL108106 0.81 TSHR (0.33) TRPV1TRPA1LMNACA1
SCHEMBL28634106 0.80 TRPV1 (0.52) TRPV1TRPA1LMNASPHK1BLM
SCHEMBL887134 0.80 SPHK1 (0.62) TRPV1TRPA1LMNASPHK1BLM
SCHEMBL31456916 0.80 TRPV1 (0.52) TRPV1TRPA1LMNASPHK1BLM
SCHEMBL14889169 0.80 SPHK1 (0.62) TRPV1TRPA1LMNASPHK1BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170290827-A1 INHIBITORS OF HEPATITIS C VIRUS GILEAD PHARMASSET LLC 2017-10-12 US disclosed
US-9655944-B2 Inhibitors of hepatitis C virus GILEAD SCIENCES, INC. (US) 2017-05-23 US disclosed
US-20160361375-A1 INHIBITORS OF HEPATITIS C VIRUS GILEAD PHARMASSET LLC 2016-12-15 US disclosed
US-9296782-B2 Inhibitors of hepatitis C virus GILEAD SCIENCES, INC. (US) 2016-03-29 US disclosed
US-20150175655-A1 INHIBITORS OF HEPATITIS C VIRUS GILEAD PHARMASSET LLC 2015-06-25 US disclosed
US-20140017198-A1 INHIBITORS OF HEPATITIS C VIRUS GILEAD PHARMASSET LLC 2014-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150175655-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, SLC10A1, GOT1 TRPV1 4269/4885TRPA1 4554/4885LMNA 2421/4885
US-20170290827-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, SLC10A1, GOT1 TRPV1 4107/4885TRPA1 4445/4885LMNA 2502/4885
US-20160361375-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, SLC10A1, GOT1 TRPV1 4107/4885TRPA1 4445/4885LMNA 2502/4885
US-20140017198-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, SLC10A1, GOT1 TRPV1 4107/4885TRPA1 4445/4885LMNA 2502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.